CNBC's Adam Bakhtiar takes on the challenge of the daily stock in 60 seconds segment and looks at Daiichi Sankyo and ArQule, where the latter's shares plunged plunged after it revealed that it would discontinue the late-stage trial of the lung cancer drug that it was co-developing with Daiichi.
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT